Capricor Therapeutics, Inc. (CAPR)
NASDAQ: CAPR · Real-Time Price · USD
21.99
+0.53 (2.47%)
At close: Oct 29, 2024, 4:00 PM
21.98
-0.01 (-0.05%)
After-hours: Oct 29, 2024, 6:21 PM EDT
Capricor Therapeutics Revenue
Capricor Therapeutics had revenue of $3.97M in the quarter ending June 30, 2024, with 1.38% growth. This brings the company's revenue in the last twelve months to $27.15M, up 187.15% year-over-year. In the year 2023, Capricor Therapeutics had annual revenue of $25.18M with 886.81% growth.
Revenue (ttm)
$27.15M
Revenue Growth
+187.15%
P/S Ratio
24.24
Revenue / Employee
$266,198
Employees
102
Market Cap
999.73M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 25.18M | 22.63M | 886.81% |
Dec 31, 2022 | 2.55M | 2.31M | 941.85% |
Dec 31, 2021 | 244.90K | -65.35K | -21.06% |
Dec 31, 2020 | 310.25K | -694.78K | -69.13% |
Dec 31, 2019 | 1.01M | -666.33K | -39.87% |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Dec 31, 2014 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Aveanna Healthcare Holdings | 1.95B |
Phibro Animal Health | 1.02B |
Avanos Medical | 682.40M |
Prothena Corporation | 217.25M |
Weave Communications | 187.00M |
Zymeworks | 62.71M |
Relay Therapeutics | 35.21M |
Mesoblast | 5.90M |
CAPR News
- 11 days ago - Capricor Therapeutics Announces Closing of Underwritten Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares - GlobeNewsWire
- 12 days ago - Capricor Therapeutics Announces Pricing of Approximately $75 Million Public Offering of Common Stock - GlobeNewsWire
- 13 days ago - Capricor Therapeutics Announces Proposed Public Offering of Common Stock - GlobeNewsWire
- 18 days ago - Capricor Therapeutics Announces Positive Long-Term Data from HOPE-2 OLE Study in Duchenne Muscular Dystrophy at 2024 World Muscle Society Congress - GlobeNewsWire
- 20 days ago - Capricor Therapeutics Announces Initiation of Rolling Submission of Biologics License Application (BLA) with U.S. FDA for Deramiocel for the Treatment of Duchenne Muscular Dystrophy - GlobeNewsWire
- 25 days ago - Capricor Therapeutics to Present Long-Term Data from HOPE-2 Open Label Extension Study at 2024 World Muscle Society Congress - GlobeNewsWire
- 4 weeks ago - Capricor Therapeutics Is Up Over 100%, Could Rise Even Higher - Benzinga
- 5 weeks ago - Capricor: DMD Treatment Focus With Deramiocel Is Likely To Pay Off - Seeking Alpha